Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting
- 1 July 2014
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 26 (3) , 217-222
Abstract
Introduction: Knowledge on the efficacy and safety of adalimumab in psoriasis patients switching from etanercept is scarce, especially on the influence that causes of etanercept discontinuation may have on adalimumab response. Objectives: To evaluate the response, adverse effects and factors that may influence the efficacy and safety of adalimumab in psoriasis patients who failed on etanercept therapy in a real-world setting. Methods: Data from all moderate to severe plaque psoriasis patients who switched from etanercept to adalimumab were extracted from a registry of biological therapies of our department. Primary endpoint was the percentage of patients achieving PASI 50 at weeks 12, 24, and 52. Secondary endpoints were the percentages of patients achieving PASI 75 and PASI 90, patients who maintained PASI values Results: Of 35 patients who fulfilled the study criteria, 82.9% achieved PASI 50 at week 12, 74.3% at week 24, and 74.3% at week 52 on adalimumab treatment. Eleven of 16 primary and 11 of 17 secondary nonresponders to etanercept responded to adalimumab. There were no treatment discontinuations due to side effects. Conclusions: Previous etanercept failure seems not influence the success and safety of adalimumab treatment in moderate to severe plaque psoriasis.Keywords
This publication has 34 references indexed in Scilit:
- Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSAJournal of Dermatological Treatment, 2013
- An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goalsBritish Journal of Dermatology, 2012
- Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension studyJournal of the European Academy of Dermatology and Venereology, 2012
- Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEALJournal of the American Academy of Dermatology, 2012
- Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanerceptBritish Journal of Dermatology, 2010
- The cytokine and chemokine network in psoriasisClinics in Dermatology, 2007
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- Infliximab in the treatment of psoriasis in patients previously treated with etanerceptJournal of the American Academy of Dermatology, 2007
- Psoriasis and its managementBMJ, 2006
- A systematic review of treatments for severe psoriasis.Health Technology Assessment, 2000